HRP20191579T1 - Spojevi kao modulatori za ror gama - Google Patents

Spojevi kao modulatori za ror gama Download PDF

Info

Publication number
HRP20191579T1
HRP20191579T1 HRP20191579T HRP20191579T1 HR P20191579 T1 HRP20191579 T1 HR P20191579T1 HR P20191579 T HRP20191579 T HR P20191579T HR P20191579 T1 HRP20191579 T1 HR P20191579T1
Authority
HR
Croatia
Prior art keywords
following
alkyl
compound
optionally substituted
cycloalkyl
Prior art date
Application number
Other languages
English (en)
Croatian (hr)
Inventor
Johanna Bakonyi
Steven Richard Brunette
Delphine Collin
Robert Owen Hughes
Xiang Li
Shuang Liang
Robert Sibley
Michael Robert Turner
Lifen Wu
Qiang Zhang
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of HRP20191579T1 publication Critical patent/HRP20191579T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/10—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20191579 2014-04-14 2015-04-10 Spojevi kao modulatori za ror gama HRP20191579T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461979231P 2014-04-14 2014-04-14
PCT/US2015/025328 WO2015160654A1 (en) 2014-04-14 2015-04-10 Compounds as modulators of ror gamma
EP15718330.2A EP3131902B1 (en) 2014-04-14 2015-04-10 Compounds as modulators of ror gamma

Publications (1)

Publication Number Publication Date
HRP20191579T1 true HRP20191579T1 (hr) 2019-11-29

Family

ID=52998264

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191579 HRP20191579T1 (hr) 2014-04-14 2015-04-10 Spojevi kao modulatori za ror gama

Country Status (35)

Country Link
US (5) US9242989B2 (enExample)
EP (2) EP3418280B1 (enExample)
JP (2) JP6282759B2 (enExample)
KR (2) KR102410069B1 (enExample)
CN (3) CN106132965B (enExample)
AP (1) AP2016009403A0 (enExample)
AR (2) AR100058A1 (enExample)
AU (2) AU2015247983B2 (enExample)
BR (2) BR112016021962A2 (enExample)
CA (1) CA2944787C (enExample)
CL (1) CL2016002421A1 (enExample)
CY (1) CY1122012T1 (enExample)
DK (1) DK3131902T3 (enExample)
EA (2) EA035063B1 (enExample)
ES (1) ES2744299T3 (enExample)
HR (1) HRP20191579T1 (enExample)
HU (1) HUE045847T2 (enExample)
IL (2) IL247419B (enExample)
LT (1) LT3131902T (enExample)
MA (1) MA46373A (enExample)
ME (1) ME03513B (enExample)
MX (1) MX370780B (enExample)
MY (1) MY182834A (enExample)
NZ (1) NZ723530A (enExample)
PE (2) PE20161572A1 (enExample)
PH (2) PH12016502019B1 (enExample)
PL (1) PL3131902T3 (enExample)
PT (1) PT3131902T (enExample)
RS (1) RS59170B1 (enExample)
SG (1) SG11201608537SA (enExample)
SI (1) SI3131902T1 (enExample)
TW (2) TWI655192B (enExample)
UA (2) UA121255C2 (enExample)
UY (1) UY36077A (enExample)
WO (1) WO2015160654A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015160654A1 (en) 2014-04-14 2015-10-22 Boehringer Ingelheim International Gmbh Compounds as modulators of ror gamma
FR3030518B1 (fr) * 2014-12-19 2018-03-23 Galderma Research & Development Derives sulfonamides en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t)
MX394388B (es) 2015-05-15 2025-03-21 Aurigene Discovery Tech Ltd Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma
JP6778259B2 (ja) 2015-10-01 2020-10-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｒｏｒガンマのモジュレーターとしてのプテリジン誘導体
CN109071516B (zh) 2015-12-15 2021-08-31 阿斯利康(瑞典)有限公司 新颖的化合物
EP3405470B1 (en) * 2016-01-20 2020-07-15 Boehringer Ingelheim International GmbH Pyrazinedihydropyrimidinone or pyridazinedihydropyrimidinone compounds as modulators of ror gamma
AR110481A1 (es) 2016-12-05 2019-04-03 Lead Pharma Holding Bv MODULADORES DE ROR g (RORg)
US20200031753A1 (en) 2017-04-06 2020-01-30 Boehringer Ingelheim International Gmbh Cyclopropyl alkyl amines and process for their preparation
WO2018229155A1 (en) 2017-06-14 2018-12-20 Astrazeneca Ab 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
CN109206346A (zh) * 2017-07-01 2019-01-15 复旦大学 叔胺类衍生物或其盐及其制备方法和用途
CN107903263B (zh) * 2017-12-28 2019-11-12 山东铂源药业有限公司 一种帕布昔利布中间体的合成方法
AU2019262169B2 (en) 2018-05-03 2024-05-02 Jiangsu Hengrui Medicine Co., Ltd. Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORy) and pharmaceutical uses thereof
US20210395185A1 (en) 2018-10-18 2021-12-23 Boehringer Ingelheim International Gmbh Scalable synthesis of optically active 1-cyclopropylalkyl-1-amines
US20230014730A1 (en) 2019-09-23 2023-01-19 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
US20220411380A1 (en) 2019-10-31 2022-12-29 Jiangsu Hengrui Medicine Co., Ltd. ACID ADDITION SALT OF RORy REGULATOR
WO2022106548A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Solid forms of a ror gamma inhibitor
WO2022106549A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Crystalline salts of a ror gamma inhibitor
WO2022106550A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Crystalline polymorphic form of a ror gamma inhibitor
WO2022106551A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Co-crystals of a ror gamma inhibitor
WO2022106547A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Process for synthesising a ror gamma inhibitor
WO2023216910A1 (zh) * 2022-05-07 2023-11-16 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为usp1抑制剂
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19
CN116178279A (zh) * 2023-03-15 2023-05-30 上海药坦药物研究开发有限公司 一种5-溴-4-环丙基-6-甲氧基嘧啶及其中间体的制备方法
AU2024267864A1 (en) * 2023-05-09 2025-11-06 11949098 Canada Inc. Inverse agonists of rar related orphan receptors (rors)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
WO2009022185A2 (en) * 2007-08-16 2009-02-19 Astrazeneca Ab 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use
CA2737472A1 (en) 2008-09-26 2010-04-01 Boehringer Ingelheim International Gmbh Azaindazole compounds as ccr1 receptor antagonists
WO2011049917A1 (en) 2009-10-21 2011-04-28 Boehringer Ingelheim International Gmbh Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists
CN103717070A (zh) * 2011-06-01 2014-04-09 贾纳斯生物治疗有限公司 新型免疫系统调节剂
DE112013002484B4 (de) * 2012-05-14 2023-05-04 Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. Pteridinketon-Derivat und Anwendungen desselben als EGFR-, BLK- und FLT3-Inhibitor
WO2015160654A1 (en) * 2014-04-14 2015-10-22 Boehringer Ingelheim International Gmbh Compounds as modulators of ror gamma
JP6778259B2 (ja) * 2015-10-01 2020-10-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｒｏｒガンマのモジュレーターとしてのプテリジン誘導体
EP3405470B1 (en) * 2016-01-20 2020-07-15 Boehringer Ingelheim International GmbH Pyrazinedihydropyrimidinone or pyridazinedihydropyrimidinone compounds as modulators of ror gamma

Also Published As

Publication number Publication date
NZ723530A (en) 2023-05-26
TWI652268B (zh) 2019-03-01
AU2019203027A1 (en) 2019-05-23
LT3131902T (lt) 2019-09-25
US20160075706A1 (en) 2016-03-17
JP6282759B2 (ja) 2018-02-21
MA46373A (fr) 2019-08-07
UA121255C2 (uk) 2020-04-27
CN106132965B (zh) 2020-02-07
EP3418280B1 (en) 2023-07-12
CY1122012T1 (el) 2020-10-14
KR20160142396A (ko) 2016-12-12
CA2944787C (en) 2023-03-14
AU2015247983A1 (en) 2016-09-08
JP2018065874A (ja) 2018-04-26
UY36077A (es) 2015-10-30
PL3131902T3 (pl) 2019-11-29
MX370780B (es) 2020-01-03
IL247419B (en) 2019-03-31
IL263878A (en) 2019-01-31
TW201625622A (zh) 2016-07-16
EA201890329A1 (ru) 2018-07-31
JP2017511357A (ja) 2017-04-20
HUE045847T2 (hu) 2020-01-28
IL263878B (en) 2019-11-28
US20150291607A1 (en) 2015-10-15
EP3131902B1 (en) 2019-06-12
AU2015247983B2 (en) 2019-05-16
AU2019203027B2 (en) 2020-07-09
PH12016502019A1 (en) 2017-01-09
KR102410069B1 (ko) 2022-06-20
CN107266450A (zh) 2017-10-20
MX2016013342A (es) 2017-01-26
PE20161572A1 (es) 2017-02-01
WO2015160654A1 (en) 2015-10-22
EA035063B1 (ru) 2020-04-23
PT3131902T (pt) 2019-09-17
PH12016502019B1 (en) 2020-10-23
KR20200040917A (ko) 2020-04-20
ES2744299T3 (es) 2020-02-24
CN107266450B (zh) 2020-07-24
CN107266454A (zh) 2017-10-20
UA120094C2 (uk) 2019-10-10
AR119454A2 (es) 2021-12-22
MY182834A (en) 2021-02-05
BR112016021962A2 (pt) 2023-01-20
ME03513B (me) 2020-04-20
US9242989B2 (en) 2016-01-26
US20180022749A1 (en) 2018-01-25
TW201841915A (zh) 2018-12-01
PE20211002A1 (es) 2021-06-01
EA201691978A1 (ru) 2017-02-28
US20170008894A1 (en) 2017-01-12
AR100058A1 (es) 2016-09-07
HK1244800A1 (zh) 2018-08-17
PH12020500252A1 (en) 2021-07-26
HK1244801A1 (zh) 2018-08-17
EA031351B1 (ru) 2018-12-28
US20190002465A1 (en) 2019-01-03
TWI655192B (zh) 2019-04-01
CA2944787A1 (en) 2015-10-22
SI3131902T1 (sl) 2019-10-30
CN107266454B (zh) 2019-08-09
DK3131902T3 (da) 2019-09-02
JP6463855B2 (ja) 2019-02-06
EP3131902A1 (en) 2017-02-22
BR112016021962B1 (pt) 2022-12-13
AP2016009403A0 (en) 2016-08-31
BR122020020657B1 (pt) 2022-12-20
RS59170B1 (sr) 2019-10-31
US9598415B2 (en) 2017-03-21
SG11201608537SA (en) 2016-11-29
KR102410076B1 (ko) 2022-06-22
CN106132965A (zh) 2016-11-16
CL2016002421A1 (es) 2017-03-24
EP3418280A1 (en) 2018-12-26

Similar Documents

Publication Publication Date Title
HRP20191579T1 (hr) Spojevi kao modulatori za ror gama
JP2017511357A5 (enExample)
HRP20250048T1 (hr) Inhibitori tyk2 i njihova uporaba
HRP20211583T1 (hr) Tienopiridini i benzotiofeni korisni kao irak4 inhibitori
HRP20210879T1 (hr) Inhibitori beta-laktamaze
HRP20200179T1 (hr) Spojevi heteroarila kao inhibitori irak i njihova uporaba
HRP20201494T1 (hr) Spojevi heteroaril-karboksamida kao inhibitori ripk2
AR086019A1 (es) COMPUESTOS DE PIRROLO SULFONAMIDA PARA MODULACION DE LA ACTIVIDAD DEL RECEPTOR HUERFANO g RELACIONADO AL RECEPTOR NUCLEAR HUERFANO RAR (RORg, NR1F3) Y PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES CRONICAS
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
AR081587A1 (es) DERIVADOS DE 5,6-DIHIDRO-2H-[1,4]OXAZIN-3-IL-AMINA UTILES COMO INHIBIDORES DE LA b-SECRETASA (BACE)
EA201591703A1 (ru) Замещенные 2-азабициклы и их применение в качестве модуляторов рецепторов орексина
ES2855732T3 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de NLRP
AR080327A1 (es) Tienopirimidinas que contienen heterocicloalquilo inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros.
AR083339A1 (es) Compuestos de quinazolina como bloqueadores de los canales de sodio
HRP20160852T1 (hr) Biciklični heterociklični spojevi kao inhibitori protein tirozin kinaze
HRP20250213T1 (hr) Spojevi i pripravci za modulaciju aktivnosti egfr mutantne kinaze
AR075332A1 (es) Dionas ciclicas como herbicidas
ECSP11011200A (es) Derivados de oxadiazale como agonista de los receptores s1p1
EA201591429A1 (ru) 2,3-дизамещенные производные 1-ацил-4-амино-1,2,3,4-тетрагидрохинолинов и их применение в качестве ингибиторов бромодомена
ECSP12012212A (es) Derivados de ariletinilo
ME02447B (me) Spoj indola i njegova farmaceutska upotreba
AR045536A1 (es) Inhibidores de la fosfodiesterasa tipo -iv
ME02672B (me) Fenil-3-aza-bicikl0[3.1.0]heks-3-il-metanoni i njihova primena kao medikament
AR098147A1 (es) Composiciones herbicidas que contienen amidas de ácido n-(1,3,4-oxadiazol-2-il)arilcarboxílico
HRP20180768T1 (hr) Triciklički heterociklički spojevi kao inhibitori fosfoinositid-3-kinaze